Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank: Figure 1.
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A think tank sponsored by the Collegium Internationale Neuropsychopharmacologium (CINP) debated the status and prospects of biological markers for psychiatric disorders, focusing on schizophrenia and major depressive disorder. METHODS: Discussions covered markers defining and predicting specific disorders or domains of dysfunction, as well as predicting and monitoring medication efficacy. Deliberations included clinically useful and viable biomarkers, why suitable markers are not available, and the need for tightly-controlled sample collection. RESULTS: Different types of biomarkers, appropriate sensitivity, specificity, and broad-based exploitability were discussed. Whilst a number of candidates are in the discovery phases, all will require replication in larger, real-life cohorts. Clinical cost-effectiveness also needs to be established. CONCLUSIONS: Since a single measure is unlikely to suffice, multi-modal strategies look more promising, although they bring greater technical and implementation complexities. Identifying reproducible, robust biomarkers will probably require pre-competitive consortia to provide the resources needed to identify, validate, and develop the relevant clinical tests.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs
Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) · Nature Genetics · doi:10.1038/ng.2711 · Cited by 2,263
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Self-citationGenetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177 · cited 1×
“This posit is in accordance with current notions of epistasis and the need for pathway analyses when examining patterns of genetic risk (Sullivan et al., 2012).”
ResultKapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980
Self-citationFillman, S. G., Cloonan, N., Catts, V. S., Miller, L. C., Wong, J., McCrossin, T., Cairns, M., & Weickert, C. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.110 · Cited by 609
Cumming, G. (2008) · Perspectives on Psychological Science · doi:10.1111/j.1745-6924.2008.00079.x · Cited by 451
Cognitive dysfunction in unipolar depression: Implications for treatment
Trivedi, M. H., & Greer, T. L. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.09.012 · Cited by 294
Cited by
Conceptualizing mental disorders as deviations from normative functioning
Marquand, A. F., Kia, S. M., Zabihi, M., Wolfers, T., Buitelaar, J. K., & Beckmann, C. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0441-1 · Cited by 433
The C factor: cognitive dysfunction as a transdiagnostic dimension in psychopathology
Abramovitch, A., Short, T., & Schweiger, A. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102007 · Cited by 269
“…not advance our understanding of the etiology, course, comorbidity, prognosis, diagnosis or the best intervention of any specific psychopathology in a meaningful way (Iacono, 2018; Kapur, Phillips, & Insel, 2012; Lilienfeld & Treadway, 2016; Scarr et al., 2015; Venkatasubramanian & Keshavan, 2016).”
BackgroundCatalan, A., Salazar de Pablo, G., Aymerich, C., Damiani, S., Sordi, V., Radua, J., Oliver, D., McGuire, P., Giuliano, A. J., Stone, W. S., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1290 · Cited by 217
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
Herbert, J., & Lucassen, P. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.12.001 · Cited by 150
Sharma, A. N., da Costa e Silva, B. F. B., Soares, J. C., Carvalho, A. F., & Quevedo, J. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.067 · Cited by 142
“The development of clinically useful biomarkers for MDD could significantly improve this scenario, allowing the identification of target populations, increasing diagnostic precision and refining therapeutic strategies (Scarr et al., 2015).”
InfluentialMillan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Self-citationBiomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Serotonin, neural markers, and memory
Meneses, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00143 · Cited by 90
“Hence, memory, amnesia, forgetting (e.g., Tellez et al., 2012b) and AD (e.g., McConathy and Sheline, 2015; Muenchhoff et al., 2015; also Scarr et al., 2015) as well as mild cognitive impairment (MCI) (Eshkoor et al., 2015) require neural markers.”
BackgroundThe dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
Diagnostic biomarkers for obsessive-compulsive disorder: A reasonable quest or ignis fatuus?
Fullana, M. A., Abramovitch, A., Via, E., López-Sola, C., Goldberg, X., Reina, N., Fortea, L., Solanes, A., Buckley, M. J., Ramella-Cravaro, V., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.08.008 · Cited by 44
Menke, A. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s146110 · Cited by 41
Kirkpatrick, R. H., Munoz, D. P., Khalid-Khan, S., & Booij, L. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.11.023 · Cited by 41
Mendez-David, I., Boursier, C., Domergue, V., Colle, R., Falissard, B., Corruble, E., Gardier, A. M., Guilloux, J.-P., & David, D. J. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00237 · Cited by 31
“Therefore, further investigation is needed to discover and validate other markers (Schmidt et al., 2011).”
BackgroundInfluential
Metadata
- Authors
- Scarr, E., Millan, M. J., Bahn, S., Bertolino, A., Turck, C. W., Kapur, S., Möller, H.-J., & Dean, B.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-21
- Volume
- 18
- Issue
- 10
- Pages
- pyv042
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2125700525
- Cited by
- 132
- References
- 19
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.